Raptiva, Efalizumab News

The Cutting Edge article by Mutos-Santos et al,1 "Response of Keratosis Lichenoides Chronica to Efalizumab Therapy," published in the August 2009 issue of the Archives , was accepted on August 12, 2008, which is prior to the recognition of the safety concerns of efalizumab.

National report - Experts disagree on the possible impact a new pediatric cancer warning for tumor necrosis factor inhibitors may have on this drug category's growth.

I have a patient with psoriasis who recently had a terrible flare when she had to stop Raptiva .

"The Misperception That Clinical Trial Data Reflect Long-term Drug Safety" is the title of a commentary in this week's Archives of Dermatology .

Commentary on: Press Release: European Medicines Agency recommends suspension of the marketing authorisation of Raptiva .

Vision problems, speech problems, weakness, loss of coordination, confusion and personality changes are often symptoms of conditions or diseases such as Progressive Multifocal Leukoencephalopathy or stoke , but could also be side effects associated with certain medications .

Research and Markets has announced the addition of the "Commercial Insight: Psoriasis - Intellectual property drives growth" report to their offering.

REPORT OF A CASE A 19-year-old man presented with a 5-year history of a widespread cutaneous eruption.

Progressive multifocal leukoencephalopathy is a rare opportunistic infection of the central nervous system caused by the JC virus.1 This virus is common and is generally innocuous in an immunocompetent host.

Cytomegalovirus is characterized by lifelong latent infection following primary infection.

Arch Dermatol. 2009;145 :865. Progressive multifocal leukoencephalopathy is a rare opportunistic infection of the central nervous system caused by the JC virus.

The Pharmaceutical Research and Manufacturers of America Senior Vice-President Ken Johnson issued a statement regarding PhRMA's support for Senate introduction of the Customs Facilitation and Trade Enforcement Reauthorization Act of 2009.

On 20 September 2004 the European Commission granted a marketing authorisation valid throughout the European Union for the medicinal product Raptiva , indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic ...

COMMENTS AND OPINIONS Efalizumab and Progression of Undiagnosed Follicular Mycosis Fungoides - Reply Sophie M. Worobec, MD In reply We respectfully disagree with Di Lernia's comment that patients with pilar MF, F-MF, or folliculotropic cutaneous T-cell lymphoma "should always be considered to have tumor-stage disease." We are familiar with the 2002 ...

Dr. Skin has a large dermatology practice with an emphasis on psoriasis. Many of his fellow dermatologists refer their most difficult patients to him.

Fuenlabrada, Spain &#8212 When other standard therapeutic approaches seem to fail, a treatment course with efalizumab may be considered for patients suffering from severe refractory atopic dermatitis, says Roman Minano, M.D., of the Department of Dermatology at the Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain.

LONDON, 8 June 2009--The European Medicines Agency has agreed to an EU-wide recall of all of the remaining batches of Raptiva , from Merck Serono .

Raptiva's exit leaves some patients without a treatment that had been working for them, dermatologists say.

EXTON, Pa., May 28 /PRNewswire/ -- BioTrends Research Group today released its syndicated report TreatmentTrends : Psoriasis, the fourth annual survey of U.S. Dermatologists .

International report - Unlike the multiple sclerosis drug Tysabri , which was pulled from the U.S. market in 2005 for safety reasons, then reintroduced, Raptiva appears permanently shelved, sources say.